Replimune Stock Surges After Trump Plans to Fire FDA Chief Marty Makary
Replimune stock jumped after news Trump may fire FDA chief, raising hopes of easier drug approvals despite past rejections.
/ 43 items
#XY News-Driven Stocks↓
Eli Lilly Dismisses Foundayo Liver Report as 'Statistical Background Noise' — RBC Maintains Outperform
Eli Lilly states that a post-launch report of hepatic failure for Foundayo (orforglipron) is not plausibly linked to the drug. RBC Capital describes it as “statistical background noise.”
Guardant Health Shares Fall After FDA Raises Concerns on AstraZeneca Breast Cancer Drug
Guardant stock fell after FDA raised doubts on a key drug study. Delay fears hurt short-term, but long-term outlook still strong.
Catalyst Pharmaceuticals Stock Surges on Angelini Pharma Buyout Rumors
Angelini Pharma may buy Catalyst Pharmaceuticals. Talks are early, but news pushed Catalyst’s stock up. No deal is certain yet.
Erasca Vows to Fight Revolution Medicines Patent Allegations – Stifel Stays Bullish
Erasca denies patent claims by Revolution Medicines, will fight back; Stifel keeps Buy rating.
Ligand Buys Xoma for $740M, Doubling Its Drug Royalty Portfolio
Ligand buys Xoma for $740M cash, boosting its drug royalty portfolio to 200+ medicines and spreading investment risk.